Cannabis Science Explained

Cannabis Science Inc.
Type:Private
Foundation:2000 (as National Healthcare Technology), reestablished in 2009
Location:Irvine, California, U.S.
Key People:Raymond C. Dabney (President, CEO, Co-Founder and Director)
Robert Melamede
(Co-Founder)[1]
Industry:Pharmaceutical
Products:Pharmaceutical products

Cannabis Science, Inc. is a biotech company based in Irvine, California. The company was incorporated in 2009 and formerly traded under the ticker CBIS on the Over-The-Counter Bulletin Board until October 2019, when their SEC license was revoked.[2]

The company's stated goal was to obtain Food and Drug Administration (FDA) approval for cannabis-based medicines, with a focus on treating skin cancer (basal and squamous cell carcinomas),[3] posttraumatic stress disorder[4] and HIV.[3] The FDA has not approved these treatments.[5]

Notes and References

  1. Web site: Radford, Bill . Company looks to create cannabis-based medicines . The Gazette . April 9, 2010 . 2019-06-19.
  2. Web site: Mayani . Mamta . Cannabis Science enters transition stage as shares halted . Seeking Alpha . 5 March 2020.
  3. Web site: Cannabis Science Appoints Former GlaxoSmithKline Global Director of HIV Research Dorothy Bray, Ph.D., to Scientific Advisory Board Focusing on CS-TATI-1 and Other Emerging Scientific Investigations . Cannabisscience.com . 2012-06-14 . 2012-07-04.
  4. Book: Fine, Doug. Too High to Fail: Cannabis and the New Green Economic Revolution. August 3, 2012. Penguin. 978-1101588895. 8.
  5. Web site: קנאביס רפואי . Tuesday, 16 March 2021